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doi:10.1016/j.jmii.2010.08.002Background: Despite the number of cases with definite diagnosis of multiple sclerosis (MS)
being on increase, the role of human herpesvirus-6 (HHV-6) infection as a trigger for MS disease
still is deliberated. Based on antibody detection and quantitative HHV-6 polymerase chain
reaction assay, this study was achieved to find out the possible association between infection
with HHV-6 and clinical progression of MS disease.
Methods: A total of 108 serum samples were obtained from 30 MS patients followed prospec-
tively for a 6-month period. These samples were analyzed for the presence of HHV-6 DNA by
nested polymerase chain reaction enzyme-linked immunosorbent assay and for anti-HHV-6
IgG titer. Activation of the disease was determined by either magnetic resonance imaging or
by clinical status of the patients. Control groups were also included.
Results: The average antibody index for the MS patients in the first sample collection was high-
er than both control groups (pZ 0.001). HHV-6 DNA was detected in the serum samples of 10 of
30 MS patients. The mean HHV-6 viral load in patients with relapsing-remitting multiple scle-
rosis (RRMS) with and without relapse was 973 and 714, respectively. Seven patients showed an
exacerbation during the study period. Of those, four patients had HHV-6 DNA in their collected
samples. The prevalence of HHV-6 DNA was significantly higher in patients with MS as compared
with control groups (p Z 0.001).ara-Clinical Medicine, Shiraz University of Medical Sciences, Meshkinfam St, 7143914693 Shiraz, Iran.
ahoo.com (A. Behzad-Behbahani).
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248 A. Behzad-Behbahani et al.Conclusions: The results indicate that HHV-6 is implicated somehow in MS disease. Over time,
rising HHV-6 IgG antibody titers together with an exacerbation and detection of HHV-6 DNA in
serum samples of some MS patients suggests possible association between the reactivation of
the virus and disease progression.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Multiple sclerosis (MS) is the most common demyelinating
disease of the central nervous system (CNS).1e3 Several
types of studies over the past decade support the hypoth-
esis that human herpesvirus-6 (HHV-6), which is associated
with a common childhood illness, roseola, is a strong
candidate to play a role in the course of MS, either as
a causal agent or as a cofactor. In recent years, HHV-6 has
been investigated as a possible causative agent for MS.
These studies have examined antieHHV-6-specific antibody
responses, HHV-6 viral DNA, or HHV-6 presence in the CNS
tissue in both MS patients and controls.4e11 However, there
are still discrepancies between the results obtained from
studies concerning how the presence of HHV-6 is linked
with clinical activity in MS patients. Active HHV-6 viral
infection in some MS patients may fluctuate over time
during the progression of the disease,12 causing variation in
viral detection.
The prevalence of MS, according to World Health Orga-
nization reports, should be about 4 in 100,000. However,
a recent study has shown that Iran could be considered as
an area with a medium to high risk of MS.13
Despite the number of cases with definite diagnosis of
MS being on the increase in this region, the role of HHV-6
active infection in this group of patients has not yet been
studied. Therefore, based on IgG antibody titer and quan-
titative HHV-6 polymerase chain reaction (PCR) assay, this
study was performed to determine the possible association
between infection with HHV-6 and clinical parameters of MS
disease progression. The results were then compared with
HHV-6 infection in normal subjects and in a group of
patients with other neurological diseases (OND).Methods
Patients and samples
Thirty MS patients (21 females and 9 males) with clinically
definite MSwere randomly selected from those attending the
Neurology Clinic at the Namazi Hospital, Shiraz University of
Medical Sciences, Shiraz, Iran during February 2008 and
January 2009. The mean duration of the MS disease was 4
years (2e20 years). Themean age of the patients withMSwas
33 years (18e45 years). Twenty-two patients had relapsing-
remitting MS (RRMS), seven had secondary progressive MS
(SPMS), and one patient had primary progressive MS (PPMS).
These patients suffered from various symptoms and clinical
manifestations. Activation of the disease (exacerbation)
was determined by either gadolinium-enhancing magneticresonance imaging (MRI) or clinical status according to the
criteria of Poser et al.14
The control patients included 20 individuals (11 females
and 9 males) with OND including motor neuron disease,
dizziness, cerebrovascular disease, migraine, meningitis,
and febrile seizure, and 20 randomly selected healthy blood
donors (10 females and 10 males). The mean age of the
control groups were 32 years (18e48 years) and 28 years
(18e35 years), respectively. All the participants gave
informed consent before the examination.
A total of 108 serum samples were collected from 30 MS
patients. Two to four serum samples were collected from
each patient during the 6 months follow-up of the study.
Surveillance serum samples were collected at first admis-
sion and then every 4e6 weeks for 6 months. MRI was
performed for the entire patients on the day of admission
and for 18 subjects at the end of the study. During the study
period, 15 MS patients were under treatment of Interferon
beta-1a (Avonex, Biogen Idec Brazil, Brazil). Serum samples
were also collected from the patients with OND and for the
normal subjects as well. All the serum samples were frozen
at 70C to be used for DNA detection by PCR and enzyme-
linked immunosorbent assay (ELISA) for detection of
specific antibodies against HHV-6.
Extraction and amplification of viral DNA
DNA extraction from serum samples was performed by the
methods detailed in Kramvis et al.,15 with some modifica-
tions. Serum (100 mL) was extracted with a proteinase K-
sodium dodecyl sulfate (SDS) extraction mix (267 mg of
proteinase K per mL, 1% sodium dodecyl sulfate, 2.5 mM
EDTA, 25 mM sodium acetate) by incubation at 70C for 2
hours. DNA was then purified by phenol-chloroform
extraction and ethanol precipitation. The resulting DNA
pellet was resuspended in 20 mL of sterile water and incu-
bated at 95C for 10 minutes to reduce or inactivate PCR
inhibitory factors. DNA extracts were then allowed to cool
and were amplified immediately.
DNAeenzyme-linked immunosorbent assay (DELISA) was
designed for quantifying HHV-6 DNA molecules in patient
serum samples. The nested primer set complementary to
the gene coding the major capsid protein (MCP) was used
with the aim of recognizing both HHV-6A and HHV-6B vari-
ants. The nucleotide sequence of the primers 50-GCTA
GAACGTATTTGCTG-30 and 50-ACAACTGTCTGACTGGCA-30
(outer pairs); 50-TCACGCACATCGGTATAT-30 and 50-CTCAA
GATCAACAAGTTG-30 (inner pairs) were used for the first and
second round of the PCR assay, respectively. The inner
primers amplify a 124-bp fragment of HHV-6. Each PCR
contained 5 mL of extracted DNA in a final volume of 50 mL
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each deoxyribonucleoside triphosphate, 1.5 mM MgCl2, 2 U
Taq DNA polymerase (Fermentas), and 0.5 mM of each
specific primer. Plasmid DNA was used as the positive
control. To exclude the possibility of contamination during
the PCR, HHV-6 negative DNA, as well as water controls,
was included in each experiment. The first round of PCR
was carried out at 94C for 3 minutes, followed by 30 cycles
of 94C for 40 seconds, 51C for 1 minute, and 72C for 40
seconds. Terminal extension of 72C for 5 minutes was
carried out after the completion of the 30 cycles. A sample
of the first round product (3 mL) was used as template for
the second round using, the conditions described for the
first round except that 10 mM of digoxigenin-11 dUTP
(Roche, Mannheim, Germany) was also added to the PCR
mixture.
Detection of amplified products
The PCR ELISA method was also used to determine the virus
load. Digoxigenin-labeled PCR products were detected by
using the commercially PCR ELISA digoxigenin detection kit
(Roche). The method was optimized for the detection of
either HHV-6A or HHV-6B DNA in the amplified product,
using 50-end-labeled biotin oligonucleotide probe (50-CT
CAAGATCAACAAGTTGCCATTTCG-30). The manufacturer’s
instructions were followed to perform PCR ELISA detection.
The final concentration of 16 pmol/mL biotin end-labeled
HHV-6 oligonucleotide probe was used as a capture probe
during hybridization. The results were expressed as net
absorbance (405/492 nm) after the optical density (OD) of the
substrate blank was automatically subtracted for each
microwell. The cut-off point for test positives was defined
as the mean of negative values plus three times the standard
deviation; the values below this were defined as negative.
Determination of the PCR sensitivity
The threshold of sensitivity of the PCR was determined
using 10-fold serial dilution of the plasmid DNA containing
MCP genes. The amplified products were analyzed by
microplate hybridization method.
Anti-HHV-6 IgG antibody
IgG antibodies to HHV-6 in the serum samples were deter-
mined by enzyme immunoassay according to manufac-
turer’s instruction (Biotin, Dublin, Ireland). The presence or
absence of HHV-6 antibodies was determined in relation to
the cut-off calibrator. An index value was calculated by
dividing the sample or control absorbance by the cut-off
calibrator value. An index value <0.9 was calculated to be
negative, an index value between 0.9 and 1.1 was equiv-
ocal, and an index value >1.1 was calculated to be positive.
Statistical analysis
Statistical difference in the prevalence of HHV-6 infection
between the tested groups was assessed by the Fisher’s
exact test. The c2 test was used to analyze the significance
of differences in serology and DNA detection.Results
Determination of PCR ELISA positive/negative
cut-off values
The “cut-off” OD 405/492 nm point between positive and
negative for detection of HHV-6 DNA by PCR ELISA in the
serum samples was found to be OD Z 0.5. To evaluate
the concentration of HHV-6 DNA in the serum samples, the
standard curve was plotted using 8  106 to 8.0 copies of
plasmid DNA versus OD (405/492 nm). The sensitivity limit of
the PCR ELISA was found to be 370 copies/mL of the HHV-6
genome in the serum samples.
Prevalence of HHV-6 DNA in MS patients and in
control groups
Using nested PCR and DELISA detection methods for the
HHV-6 MCP gene, cell-free DNA was detected in the serum
samples of 10 of 30 (33.3%) patients with MS. These results
were in contrast to 5% (one of 20) either in OND or normal
blood donors control groups. The difference between
prevalence of HHV-6 DNA in MS patients and in control
groups was statistically significant (p Z 0.001).
The viral DNA was detected at least in one serum sample
along the 6 months follow-up in 41% of RRMS samples, 14%
of SPMS samples, and none of the primary progressive MS
(Table 1). We did not find any significant differences
(p Z 0.36) between the presence of viral DNA in serum
samples of RRMS and the SPMS group. However, a larger
sample size is needed for better evaluation.
With respect to viral load in serum samples of MS patients,
HHV-6 DNA copy number ranged from undetectable to
1.5 103/mL. The lowest HHV-6 DNAmolecules (427 copies/
mL) were found in patients with remission and the highest
HHV-6 DNA copy numbers (1.5  103 copies/mL) were found
in the serum samples of the patients with exacerbation.
HHV-6 viral load during active infection was significantly
greater (p < 0.001) than remission: 765 versus 491 genome/
mL of collected serum samples (64% of increase in viral load
during acute attack). During study time, 7 of 24 (28.6%) MS
patients whose results were completely available were
exacerbated. HHV-6 DNA was detected in four of seven
patients with exacerbation (Table 1).
MRI was performed for 18 subjects at the end of study.
The last MRI results revealed some new demyelinating
plaques in three HHV-6 positive individuals with exacerba-
tion, when compared with the previous MRI findings. HHV-6
DNA was detected either in 4 of 15 (27%) of Avonex treated
or in 6 of 15 (40%) untreated MS patients. HHV-6 DNA was
also detected in one serum sample of the normal controls
(1,200 DNA molecules/mL) and in one serum sample of the
patients with OND (900 DNA molecules/mL). Both of them
were negative for IgG antibody in their serum samples.
Prevalence of anti-IgG in MS patients and in control
groups
The prevalence of positive HHV-6 IgG antibody in MS
patients, in patients with neurological diseases other than
MS, and in normal subjects was found to be 100% (30 of 30),
Table 1 Mean viral load for HHV-6 and clinical findings in patients with multiple sclerosis
HHV-6 DNA (þ) Mean HHV-6 DNA copies/mL HHV-6 IgG (þ)
MS (n Z 30)
RRMS (n Z 22) 9 766 22
SPMS (n Z 7) 1 610 7
PPMS (n Z 1) None None 1
Exacerbation (n Z 7) 4 882 7
New plaque in MRI 3 759 3
Avonex treatment (n Z 15) 4 828 4
Other neurologic disorders (n Z 20) 1 900 14
Healthy controls (n Z 20) 1 1,200 15
HHV-6 Z human herpesvirus-6; MRI Z magnetic resonance imaging; MS Z multiple sclerosis; PPMS Z primary progressive MS;
RRMS Z relapsing-remitting MS; SPMS Z secondary progressive MS.
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average antibody index for the MS patients in the first
sample collection was 2.68 versus 1.4 for both the control
groups (p Z 0.001).
Discussion
Many studies have implicated HHV-6 in the etiology of MS;
however, this association is controversial, and, as is the case,
experimental evidence linking this organism to MS is equiv-
ocal. Immunohistochemical analysis of MS plaques has
revealed a concentration of an HHV-6 antigen in oligoden-
dreocytes, the CNS cell responsible for the formation and
maintenance of myelin.7,16 An increased incidence of IgG
and IgM antibodies against HHV-6 in both serum and CSF in MS
patients has been reported.17,18 It has been indicated that
HHV-6 DNA is more frequent in MS patients than in healthy
blood donors.19 In several studies, on the other hand, HHV-6
DNA was not detected in different clinical samples.
However, there is still controversy about this theory. In the
present study, we have determined the seroprevalance and
the quantitative frequency of HHV-6 DNA in serum samples of
the patients with MS in different courses of illness. The
results were then compared with two control groups
including normal individuals and patients with neurological
diseases other than MS. Since the presence of HHV-6 DNA in
the serumwould be an indicator of active infection, we tried
to determine the viral load during active infection. The
prevalence of HHV-6 DNA was significantly higher in patients
withMS (33.3%) comparedwith thosewith other neurological
disorders and the normal individuals (5%). We found a higher
HHV-6 frequency of active infection in RRMS patients than in
the other groups. A significant increase in viral load during
active infection in comparison with remission (p < 0.001)
suggesting the possible exposure of HHV-6 antigen to the
immune system of the host. To realize the outcome of active
HHV-6 infection on clinical symptoms of patients with MS,
a quantitative DELISA was established. In four patients with
exacerbation, viral DNA load in the serum samples was found
to be 830, 610, 1,400, and 690 molecules of DNA/mL
respectively. The absence of HHV-6 in serum sample of
patients with active MS may be associated with an early
stage of viral replication.19 The last MRI results revealed
some new demyelinating plagues in three HHV-6 positive
individuals, when compared with their previous MRI results.
Of those, two patients had exacerbation during study time,but the third one had no exacerbation. Our results confirm
the relationship between the active lesions on MRI scans and
patterns of disease activity in some MS patients. Although
our DELISA was not able to detect less than 370 molecules of
HHV-6 DNA/mL of the serum samples, using an advanced
quantitative real time PCR technique, might improve
detection of more active HHV-6 infections in MS patients.
MS patients have increased titer of serum antibody in
comparison with control groups. The analysis by ELISA
showed that the MS patients had increased prevalence and
higher titer of HHV-6 antibody than the control groups. The
comparison of the antibody titer in the first sample
collection of the MS patients with control groups suggests
that either the virus may possibly replicate in MS patients
intermittently or the patients had been exposed to rein-
fection. The prevalence of HHV-6 IgG antibody in all serum
samples collected from MS patients (100%) indicates that all
MS patients were infected by HHV-6.
Among our results, the prevalence of HHV-6 DNA was not
influenced by treatment with beta interferon. These results
are compatible with those reported by Alvarez-Lafuente
et al.20
However, it has not been indicated that the current
dosage regimens (for MS patients) produce serum levels of
the drug capable of suppressing the replication of HHV-6.
In conclusion, results indicate that HHV-6 is implicated
somehow in MS disease. The rise in HHV-6 IgG antibody
titer together with an exacerbation and detection of HHV-
6 DNA in the serum samples of some MS patients suggests
possible association between the reactivation of the virus
and disease progression. Nevertheless, further studies
concerning the role of HHV-6 in MS disease are clearly
warranted.
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